Science News
from research organizations

New drug combination treats hepatitis C patients also infected with HIV

Date:
July 21, 2015
Source:
University of California, San Diego Health Sciences
Summary:
A new combination of drugs that effectively treats hepatitis C (HCV) patients co-infected with human immunodeficiency virus type 1 (HIV) has been discovered by researchers who report that the novel treatment has a 97 percent success rate in co-infected patients .
Share:
FULL STORY

Roughly 20 to 30 percent of patients with hepatitis C virus (HCV) are also infected with human immunodeficiency virus type 1 (HIV). Both blood-borne viruses share the same modes of transmission, but many HCV medications currently have significant limitations due to adverse interactions with HIV treatments. Researchers at University of California, San Diego School of Medicine report a new combination that effectively treats HCV in patients co-infected with HIV.

The study, published online in the New England Journal of Medicine, found the combination of HCV drugs daclatasvir and sofosbuvir -- both pills -- cured HCV in 97 percent of patients also infected with HIV.

"In many HCV/HIV co-infected patients, HCV therapies can have a strong interaction with HIV medications that complicate or potentially exclude them from HCV treatment," said David Wyles, MD, lead author of the study in the Division of Infectious Diseases. "This study is novel because it shows the new drug combination was not compromised when used with a wide range of HIV medications, increasing the number of HCV/HIV patients who can be treated without modifying their HIV medications."

The 12-week study involved 151 patients and was the first to test this treatment regimen in those with HIV/HCV. Patients who participated in the clinical trial were closely monitored up to 24 weeks post treatment.

Another reason the study findings are important, said Wyles, is because HCV is a major cause of chronic liver disease in the United States, and liver damage progresses more rapidly in those also infected with HIV.

"Liver disease is a leading cause of death among HIV patients, so it is a high priority to treat co-infected patients and reduce the potentially fatal effect," said Wyles, also associate professor of medicine at UC San Diego School of Medicine.

Sofosbuvir is already approved for use in the United States; daclatasvir is scheduled to be reviewed by the Food and Drug Administration in August.

"These findings are very exciting in the infectious diseases world, as they could help an entire demographic that has historically struggled finally receive successful treatment for HCV," said Wyles.


Story Source:

Materials provided by University of California, San Diego Health Sciences. Original written by Michelle Brubaker. Note: Content may be edited for style and length.


Journal Reference:

  1. David L. Wyles, Peter J. Ruane, Mark S. Sulkowski, Douglas Dieterich, Anne Luetkemeyer, Timothy R. Morgan, Kenneth E. Sherman, Robin Dretler, Dawn Fishbein, Joseph C. Gathe, Sarah Henn, Federico Hinestrosa, Charles Huynh, Cheryl McDonald, Anthony Mills, Edgar Turner Overton, Moti Ramgopal, Bruce Rashbaum, Graham Ray, Anthony Scarsella, Joseph Yozviak, Fiona McPhee, Zhaohui Liu, Eric Hughes, Philip D. Yin, Stephanie Noviello, Peter Ackerman. Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1. New England Journal of Medicine, 2015; 150721143019008 DOI: 10.1056/NEJMoa1503153

Cite This Page:

University of California, San Diego Health Sciences. "New drug combination treats hepatitis C patients also infected with HIV." ScienceDaily. ScienceDaily, 21 July 2015. <www.sciencedaily.com/releases/2015/07/150721194221.htm>.
University of California, San Diego Health Sciences. (2015, July 21). New drug combination treats hepatitis C patients also infected with HIV. ScienceDaily. Retrieved May 23, 2017 from www.sciencedaily.com/releases/2015/07/150721194221.htm
University of California, San Diego Health Sciences. "New drug combination treats hepatitis C patients also infected with HIV." ScienceDaily. www.sciencedaily.com/releases/2015/07/150721194221.htm (accessed May 23, 2017).

RELATED STORIES